Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States

In 2012, the Food and Drug Administration approved use of bedaquiline fumarate as part of combination therapy for multidrug-resistant tuberculosis (MDR TB). We describe treatment outcomes, safety, and tolerability of bedaquiline in our case series. Data on patients started on bedaquiline for MDR TB...

Celý popis

Podrobná bibliografia

Vydané v:	Clinical infectious diseases Ročník 71; číslo 4; s. 1010
Hlavní autori:	Mase, Sundari, Chorba, Terence, Parks, Samuel, Belanger, Ann, Dworkin, Felicia, Seaworth, Barbara, Warkentin, Jon, Barry, Pennan, Shah, Neha
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 14.08.2020
Predmet:	Antitubercular Agents - adverse effects Diarylquinolines - adverse effects Humans Retrospective Studies Treatment Outcome Tuberculosis, Multidrug-Resistant - drug therapy United States - epidemiology United States treatment adverse event multidrug-resistant tuberculosis bedaquiline outcome
ISSN:	1537-6591, 1537-6591
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!